Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 4/20 | 0.52 |
| ▸ | EGFR | P00533 | 4/20 | 0.51 |
| ▸ | PDE5A | O76074 | 1/20 | 0.50 |
| ▸ | PI4KA | P42356 | 1/20 | 0.47 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.47 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 2/20 | 0.47 |
| ▸ | RET | P07949 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAK | O14976 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29761271 | 1.00 | MAP4K4 (0.52) | MAP4K4EGFRPDE5API4KAPI4K2B | |
| SCHEMBL3166753 | 0.89 | PDE5A (0.57) | MAP4K4EGFRPDE5API4KAPI4K2B | |
| SCHEMBL30103402 | 0.89 | PDE5A (0.57) | MAP4K4EGFRPDE5API4KAPI4K2B | |
| SCHEMBL19381685 | 0.84 | EGFR (0.50) | EGFRKITRETKDRENPP1 | |
| SCHEMBL31469297 | 0.83 | EGFR (0.49) | EGFRKITRETKDRENPP1 | |
| SCHEMBL8230611 | 0.83 | EGFR (0.51) | MAP4K4EGFRPDE5API4KAPI4K2B | |
| SCHEMBL30968992 | 0.83 | EGFR (0.51) | MAP4K4EGFRPDE5API4KAPI4K2B | |
| SCHEMBL28704127 | 0.83 | EGFR (0.49) | EGFRKITRETKDRENPP1 | |
| SCHEMBL26581822 | 0.83 | MAP4K4 (0.49) | MAP4K4EGFRPI4KAPI4K2BPI4K2A | |
| Hydrochloric Acid SCHEMBL28068945 | 0.81 | EGFR (0.48) | EGFRKITRETKDRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023195773-A1 | HETEROARYL DERIVATIVE AND USE THEREOF | 보로노이 주식회사 | 2023-10-12 | — | — | WO | disclosed |
| WO-2023195773-A1 | HETEROARYL DERIVATIVE AND USE THEREOF | 보로노이 주식회사 | 2023-10-12 | — | — | WO | disclosed |
| US-20230025510-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
| CN-112707869-B | Dacotinib impurity and preparation method thereof | 扬子江药业集团有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-108659005-B | Quinazoline derivatives as EGFR inhibitors | 南京明德新药研发股份有限公司 | 2019-05-07 | — | — | CN | disclosed |
| CN-108640928-B | Quinazoline compounds as EGFR inhibitor | 南京明德新药研发股份有限公司 | 2019-05-03 | — | — | CN | disclosed |
| EP-2611797-B1 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | HANMI SCIENCE CO LTD (KR) | 2016-12-28 | — | — | EP | disclosed |
| CN-103237801-B | Quinoline or quinazoline derivatives having apoptosis-inducing activity on cells | HANMI HOLDINGS Co.,Ltd. (KR) | 2015-11-25 | — | — | CN | disclosed |
| US-8835458-B2 | Quinoline or quinazoline derivatives with apoptosis inducing activity on cells | HANMI SCIENCE CO., LTD (KR) | 2014-09-16 | — | — | US | disclosed |
| EP-2611797-A2 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | Hanmi Science Co., Ltd. (KR) | 2013-07-10 | — | — | EP | disclosed |
| US-20130165386-A1 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | HANMI SCIENCE CO., LTD (KR) | 2013-06-27 | — | — | US | disclosed |
| WO-2012169785-A9 | SYMMETRICALLY STRUCTURED QUINAZOLINE DERIVATIVES | HANMI SCIENCE CO., LTD. (KR) | 2013-05-23 | — | — | WO | disclosed |
| WO-2012030160-A2 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | HANMI HOLDINGS CO., LTD. (KR) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165386-A1 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS | CASP7, API5, BAX | MAP4K4 1375/4885EGFR 4690/4885PDE5A 2095/4885 |
| US-20230025510-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES | ERBB2, EGFR, ERBB3 | MAP4K4 166/4885EGFR 2/4885PDE5A 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.